The molecular categories that determine everything from how you take a compound to how your body processes it.

Sources and References

Related Guides

Quick Facts

Table of Contents

1. The Size Spectrum: Where Peptides Fit
2. Small Molecules: The Oral-Friendly Category
3. Peptides: The Peptidings Core
4. Modified Peptides: Where the Boundaries Get Fuzzy
5. Proteins and Biologics: The High-Complexity Category
6. Why the Category Matters: The Practical Differences
7. Where Peptidings Compounds Land
8. Plain English FAQ

↑ Back to top

The Size Spectrum: Where Peptides Fit

Molecular weight is the first dividing line. Chemists use approximate thresholds—not hard rules, but conventions useful enough that they’ve stuck around.

Small molecules are compounds under roughly 500 Daltons (Da). A Dalton is the atomic mass unit—the mass of a hydrogen atom. For context, glucose weighs about 180 Da. Aspirin is 180 Da. Water is 18 Da. Most drugs you can swallow fall in this range.

Peptides are chains of amino acids, usually between 2 and 50 amino acids long. Because amino acids have a consistent molecular weight (around 110 Da on average), a 10-amino-acid peptide weighs roughly 1,100 Da. A 50-amino-acid peptide lands around 5,500 Da. This range—roughly 500 Da to 5,000–6,000 Da—is the working definition of peptide. It’s a convention, not a law of physics.

Proteins and biologics are chains longer than 50 amino acids, usually much longer. Insulin has 51 amino acids (5,808 Da). Follistatin has 344 amino acids. Cerebrolysin is a mixture of small proteins and peptide fragments. These larger molecules require different manufacturing (biological systems, not chemical synthesis), different stability protocols, and different regulatory pathways.

The categories overlap at the edges. A 45-amino-acid chain is technically a peptide by most definitions but sits functionally close to protein territory. A small-molecule drug conjugated to a fatty acid—like semaglutide—blurs the boundary. These edge cases are where the chemistry gets interesting, and they’re exactly where you need to understand the practical differences.

↑ Back to top

Small Molecules: The Oral-Friendly Category

Small molecules have one huge advantage: they can survive your stomach and intestines. Most small drugs are designed to do exactly that.

Here’s why this matters: your digestive system is a hostile environment for fragile molecules. Stomach acid is corrosive. Your gut contains enzymes (peptidases, proteases) that break apart peptide bonds—which is exactly what amino acid chains are held together with. Your intestinal epithelium is selective; it only absorbs molecules it recognizes or that fit through specific transporters. Once you get past the gut, your liver metabolizes drugs before they reach your bloodstream (a process called first-pass metabolism).

Small molecules are usually designed to either survive this gauntlet or be absorbed before they reach the worst of it. Many small-molecule drugs include chemical modifications that make them resistant to acid and enzymes. Some are lipophilic (fat-soluble), which helps them cross cell membranes and get absorbed quickly. Others bind to transporters that actively move them across intestinal cells. The result: you can take them as a pill, and they work.

Examples on Peptidings:

• MK-677 (ibutamoren, ~528 Da): A spiroindoline—a synthetic small molecule, not a peptide. It’s orally bioavailable, hits a half-life of 24 hours, and you take it as a pill. MK-677 demonstrates why Peptidings always flags this compound as “not a peptide.” It’s in nearly every peptide article on the site, but it’s fundamentally different from the compounds around it. The distinction matters because it tells you immediately: oral dosing, daily timing, different stability rules, different manufacturing process.

• 5-Amino-1MQ (~300 Da): Another small molecule. Orally active. Designed to inhibit quinolone oxidase (QO), an enzyme involved in NAD+ metabolism. The oral bioavailability is the whole point of the design.

Small molecules are also generally cheaper to manufacture—they’re made through standard chemical synthesis in a lab, not in biological systems. They’re shelf-stable, often stable at room temperature, which is why you can buy them in bottles and store them in a closet. The trade-off is that most small molecules don’t penetrate as deeply into tissue as peptides do, and they often have shorter target specificity—they bind multiple receptors, not just one.

↑ Back to top

Peptides: The Peptidings Core

A peptide is a chain of amino acids—the building blocks of all proteins. The difference between a peptide and a protein is mostly just length. Amino acids link via peptide bonds, and when your digestive system encounters that bond, it breaks it apart. This is why you cannot take most peptides as a pill.

The peptide form:

Peptides on Peptidings typically fall in the 5–15 amino acid range, though we cover some longer ones. A 5-amino-acid peptide (ipamorelin) weighs around 640 Da. A 15-amino-acid peptide (BPC-157) weighs roughly 1,500 Da. These are still small enough to be synthesized via solid-phase peptide synthesis (SPPS)—a chemical process that chains amino acids one at a time, in a lab, without needing living cells.

This is the crucial point: peptides can be made in a lab through chemistry. You don’t need a manufacturing facility with bioreactors and recombinant DNA technology. A compounding pharmacy can synthesize peptides using SPPS equipment. This is why most compounding pharmacies manufacture peptides—because the barrier to entry is lower than for biologics.

Examples on Peptidings:

• BPC-157 (body protection compound-157, 15 amino acids, ~1,500 Da): A synthetic peptide fragment. Originally discovered in human gastric juice. Studied for wound healing, tendon repair, and GI protection. Orally bioavailable in some formulations (though evidence is mixed). Also available for subcutaneous or intramuscular injection.

• Ipamorelin (5 amino acids, ~640 Da): A growth hormone secretagogue peptide. Selective for the GH secretagogue receptor. Subcutaneous injection only. Half-life of about 2 hours, which is why it’s usually dosed multiple times per day.

• TB-500 (synthetic fragment, 7 amino acids): A synthetic version of a naturally occurring 43-amino-acid peptide thymosin beta-4. Shorter, easier to manufacture. Studied for muscle repair and recovery.

The peptide problem: stability and dosing.

Peptides are less stable than small molecules because peptide bonds are vulnerable to hydrolysis (breaking apart in water) and oxidation (degradation from oxygen exposure). This is why peptides are typically stored lyophilized (freeze-dried) and kept at 2–8°C (35–46°F). Once reconstituted with sterile water, they degrade over days or weeks. Small molecules can sit on a shelf. Peptides need refrigeration and careful reconstitution protocols.

Half-lives are also short—often 2–4 hours for unmodified peptides. This means you need to dose frequently, or you need to modify the peptide to make it last longer. The modifications are where the magic—and the complexity—happens.

↑ Back to top

Modified Peptides: Where the Boundaries Get Fuzzy

This is where the story gets interesting. Because unmodified peptides have short half-lives and need frequent injections, chemists engineer modifications to make them last longer, absorb better, or cross barriers they normally couldn’t cross.

These modifications blur the line between peptide and biologic. The base molecule is still a peptide—still a chain of amino acids. But it’s no longer a “natural” peptide. It’s engineered. Heavily modified. Sometimes to the point where calling it a peptide is technically correct but practically misleading.

Fatty acid conjugation:

The most common modification is attaching a fatty acid (a lipid) to the peptide backbone. This is how semaglutide—one of the most famous peptides in the world—extends its half-life from about 2 minutes to 7 days.

Here’s the mechanism: a GLP-1 receptor agonist (unmodified) has a half-life measured in minutes because your kidneys filter it out immediately. The peptide is small enough to pass through the glomerular filtration barrier. Attach a C18 diacid fatty acid—essentially a long-chain fat—to the peptide backbone, and three things happen: (1) the modified peptide is larger, harder for kidneys to filter; (2) the fatty acid is albuminophilic, meaning it binds strongly to albumin, the most abundant protein in your blood, which then carries the peptide around; (3) the albumin-peptide complex is much more resistant to enzymatic degradation. The result is a 7-day half-life.

This makes semaglutide practical—one injection per week instead of multiple per day. It also changes the whole pharmacology. The 7-day half-life means steady-state accumulation; the dose you take on day 1 is still circulating on day 6. It changes when you notice side effects, how long adverse events last, and what dosing protocols look like.

Semaglutide is still, technically, a peptide—it’s still a chain of amino acids. But it’s a heavily modified peptide. The modification is so extensive that calling it just “a peptide” obscures what it actually is: an engineered construct designed to survive in your bloodstream.

PEGylation:

Another common modification is PEGylation—attaching polyethylene glycol (PEG) chains to the peptide. PEG is an inert polymer that makes the peptide less visible to the immune system and more stable in circulation. PEG-MGF (PEGylated mechano growth factor) is an example. The PEG chains extend half-life and improve stability without changing the underlying amino acid sequence.

DAC conjugation:

CJC-1295 comes in two forms: (no DAC) and (with DAC). The DAC (drug affinity complex) version is conjugated to a maleimide linker that covalently binds to albumin in your bloodstream. This extends half-life from roughly 30 minutes (unmodified) to about 6–8 days. The engineering is so effective that CJC-1295 with DAC was the subject of a failed FDA application in 2009 (it showed efficacy but safety concerns halted development). Still, it’s a powerful example of how modifications transform a simple peptide into something that behaves like a small biologic.

The question: are these still peptides?

By strict definition, yes—they’re amino acid chains. By functional definition, they’re engineered constructs that blur the peptide/biologic boundary. Some researchers call them “peptide-like compounds” or “modified peptides” to make the distinction clear. The regulatory system often treats them differently from both small molecules and traditional biologics—sometimes as drugs (small molecules are regulated as drugs, biologics as biologics), sometimes in gray zones where the pathway isn’t entirely clear.

What matters for you: a modified peptide with a 7-day half-life behaves more like a traditional drug than a short-acting peptide does. The dosing interval changes. The accumulation in your system changes. The stability profile changes. These are the practical consequences of modification.

↑ Back to top

Proteins and Biologics: The High-Complexity Category

When a chain of amino acids exceeds roughly 50 amino acids, the definition shifts. You now have a protein—or more precisely, in regulatory and manufacturing terms, a biologic.

Biologics are fundamentally harder to make than peptides. You cannot synthesize them reliably with solid-phase peptide synthesis. The standard is recombinant DNA technology: you insert a gene (DNA) coding for the protein into a living cell (usually bacteria, yeast, or mammalian cells), let the cell manufacture the protein, and then purify it. This requires biological systems—fermentation tanks, cell culture, purification infrastructure.

The regulatory pathway is different. The FDA regulates biologics under the Biologic License Application (BLA) pathway, which is more complex and more rigorous than the standard New Drug Application (NDA) for small molecules. Manufacturing facilities must meet cGMP standards specific to biologics, including sterility assurance, endotoxin testing, and validation of cell lines.

Examples on Peptidings:

• Follistatin (344 amino acids): A naturally occurring protein that inhibits myostatin, a regulator of muscle growth. Studied for muscle wasting and performance. Follistatin is a true protein—too long to synthesize in a lab, manufactured recombinantly.

• Cerebrolysin: A mixture of amino acids and small peptide fragments derived from pig brain tissue. Not a single pure compound but a complex mixture. Regulated in some countries as a biologic, in others as a pharmaceutical preparation. The regulatory status varies because the manufacturing (extraction from biological tissue) doesn’t fit cleanly into standard categories.

• Insulin (51 amino acids): The canonical biologic. Originally extracted from pancreatic tissue, now manufactured recombinantly. Regulated as a biologic despite decades of clinical use.

Why biologics are harder:

Manufacturing precision is more difficult. Chemical synthesis can make a small molecule with 99%+ purity every time. Recombinant manufacturing is less precise. Cell lines produce proteins with variations—post-translational modifications (phosphorylation, glycosylation, etc.) that can vary batch to batch. Purity is usually 95–98%, not 99%+. This is why biologics require extensive characterization of every batch.

Stability is more fragile. Proteins denature (unfold and lose function) from heat, pH changes, oxidation, and mechanical stress. Most biologics require refrigeration (2–8°C) or freezing (–20°C or colder). Some are freeze-dried, but reconstitution protocols are strict. A small molecule bottle lasts months in a closet. A biologic vial lasts weeks refrigerated.

Cost is higher. Manufacturing biologics requires bioreactors, specialized equipment, and regulatory expertise. A small-molecule drug might cost $10–50 to manufacture per dose. A biologic might cost $500–1,000+ per dose before markups.

Shelf-life is shorter. Most biologics are stable for 18–24 months refrigerated. Some last only a few months. Once opened or reconstituted, the window is days.

↑ Back to top

Why the Category Matters: The Practical Differences

Now that you understand what the categories are, here’s why they matter in the real world.

Route of Administration

Small molecules can often be swallowed because they survive stomach acid and digestion. Most peptides cannot—they’re broken apart by digestive enzymes before they can be absorbed. This means:

• Small molecules: oral, intravenous, intramuscular, topical, intranasal, and more
• Peptides: primarily subcutaneous or intramuscular injection; oral absorption is rare and unreliable
• Biologics: subcutaneous, intramuscular, or intravenous injection

This is the most immediately practical difference. MK-677 is a pill. BPC-157 is an injection (though some oral formulations claim activity, evidence is inconsistent). Follistatin is an injection. The route of administration determines convenience, compliance, side effects, and cost. Oral dosing is convenient; needle anxiety is real; intravenous requires clinical infrastructure.

Stability and Storage

• Small molecules: generally stable at room temperature, insensitive to light or minor temperature fluctuations. A bottle of MK-677 stored in a closet remains stable for years.
• Peptides: unstable without refrigeration. Lyophilized and stored at 2–8°C (35–46°F). Once reconstituted, stable for days to weeks depending on formulation and reconstitution buffer. Susceptible to oxidation, hydrolysis, and bacterial contamination. This is why reconstitution protocols matter—the buffer, sterility, and storage temperature all affect stability.
• Biologics: similar to peptides—refrigeration required, lyophilized for long-term storage, careful reconstitution protocols. Some biologics are freeze-dried; others are in solution. The cold chain is critical.

Stability has downstream consequences: shipping costs (peptides and biologics need insulated packaging), equipment costs (you need a refrigerator or freezer), and preparation complexity (you must reconstitute peptides before injection, which introduces contamination risk if protocols aren’t followed).

Regulation and Manufacturing Pathways

The regulatory pathway depends on the category:

• Small molecules: FDA New Drug Application (NDA). Standard pharmaceutical approval. Manufacturing can occur in a compounding pharmacy (for some), a pharma company, or a contract manufacturer. Regulatory bar is high but well-defined.

• Peptides: This is murky. Some peptides are regulated as drugs (NDAs). Some are synthesized by compounding pharmacies under state pharmacy law (not FDA approval). Some exist in gray zones where they’re not explicitly approved but are manufactured under certain state legal frameworks. When Peptidings mentions that a compound is “not FDA-approved,” this is often because the peptide exists in this gray zone—synthesized and distributed, but not through the FDA drug approval pathway.

• Biologics: FDA Biologic License Application (BLA). Requires manufacturing in an FDA-approved facility. Compounding pharmacies cannot manufacture biologics—the regulatory and technical barriers are too high. This is why you cannot get follistatin from a local compounding pharmacy; it requires a licensed biologics manufacturer.

This has enormous practical consequences. If a compound is approved as a drug (small molecule or biologic), it’s manufactured under strict quality standards (cGMP—current good manufacturing practice). If it’s manufactured by a compounding pharmacy, it’s regulated differently—quality standards vary by state, and oversight is less stringent. The difference between an FDA-approved drug and a compounded peptide is massive from a quality, purity, and sterility perspective.

Half-Life and Dosing Frequency

The category heavily influences how long the compound lasts in your body.

• Small molecules: highly variable. MK-677 has a 24-hour half-life; aspirin is 20 minutes; some small molecules last days. Usually dosed once or twice daily.
• Unmodified peptides: typically 2–4 hours. Requires frequent dosing (multiple times per day) to maintain steady-state levels. Example: ipamorelin is often dosed three times daily.
• Modified peptides: extended via the engineering. Semaglutide (with the C18 fatty acid) lasts 7 days. CJC-1295 with DAC lasts 6–8 days. This changes the entire dosing structure and compliance picture.
• Biologics: variable depending on the protein. Insulin has a half-life of about 6 minutes (IV) but is formulated for subcutaneous absorption over hours. Some biologics are dosed daily, others weekly or monthly.

Half-life directly determines how often you need to dose and whether compound accumulates in your system. A 24-hour half-life means you reach steady-state in about 5 days (roughly 5 half-lives). A 7-day half-life means you’re still accumulating compound on day 35. This affects side-effect timing, dose adjustments, and washout periods if you stop taking the compound.

Manufacturing and Quality

• Small molecules: can be synthesized in a lab, batch-tested for purity, and characterized fully. A 99%+ pure small molecule is standard. Manufacturing is scalable and relatively cheap.

• Peptides: synthesized in a lab via SPPS, but purity is typically lower than small molecules (95–98%). Compounding pharmacies synthesize peptides; quality depends on the pharmacy’s standards, equipment, and validation. There is no guaranteed quality standard across compounding pharmacies—some are excellent, others are mediocre.

• Biologics: manufactured in biological systems (cells), so batch-to-batch variation is higher. Purity is typically 95–98%. Quality assurance is extensive—each batch must be tested for sterility, endotoxin, potency (bioassay), and identity (protein sequencing, peptide mapping). Manufacturing is regulated by the FDA, so quality standards are consistent.

Here’s the key: if you buy a peptide from a compounding pharmacy, you are trusting that pharmacy’s quality standards. There is no FDA stamp of approval on the vial. There is no guarantee of purity, sterility, or potency. If you buy a small-molecule drug from a pharmacy, it’s FDA-approved—manufactured under cGMP, tested in the clinic, and guaranteed to meet purity standards. The difference is enormous.

Intellectual Property and Development

Small molecules are easier and cheaper to develop. Peptides are harder—longer half-lives require engineering (semaglutide took Novo Nordisk years to develop). Biologics are the hardest—manufacturing scale-up, regulatory approval, and clinical trials all add cost and time.

This is why you see so many copycat peptides but fewer competing versions of biologics. A small-molecule drug is patentable for 20 years; after the patent expires, generics flood the market (and prices drop). Biologics have longer market exclusivity (12 years in the US), but genuine therapeutic competitors are rare. Semaglutide and tirzepatide are both GLP-1 agonists, but they’re different molecules with different properties—not interchangeable generics.

↑ Back to top

Where Peptidings Compounds Land

Here’s a quick reference table mapping key Peptidings compounds to their category. Use this to orient yourself.

Key observations:

• The orange zone (modified peptides): semaglutide, tirzepatide, CJC-1295 with DAC, and retatrutide are where the category boundaries blur. They’re technically peptides—still amino acid chains—but so heavily engineered that they function more like small-molecule drugs with extended half-lives. The modifications are load-bearing.

• The MK-677 anomaly: MK-677 appears in nearly every Peptidings article on growth-hormone secretagogues and weight loss, but it is not a peptide. It’s a small molecule. Peptidings always notes this because the distinction tells you something important: MK-677 is oral, stable at room temperature, and has a 24-hour half-life. It solves different problems than peptides solve.

• Unmodified peptides vs. modified: the boundary between “quick and frequent dosing” vs. “convenient weekly dosing” is almost entirely about modification. BPC-157 unmodified needs multiple doses per day (if the 2–4 hour half-life estimate is correct). Semaglutide modified lasts a week.

• The compounding pharmacy limitation: every peptide in the table above except semaglutide, tirzepatide, and retatrutide can theoretically be synthesized by a compounding pharmacy. Follistatin cannot—it’s a biologic and requires recombinant manufacturing. FDA-approved peptides (which don’t really exist on this list except the highly modified ones) are manufactured by licensed pharmaceutical companies. The compounding pharmacy/manufactured biologic split is a hard regulatory line.

↑ Back to top

The Compounding Pharmacy Angle

One more crucial point: the distinction between these categories determines what’s available through compounding pharmacies versus what must come from licensed manufacturers.

Compounding pharmacies synthesize peptides. They do this by purchasing amino acids and using solid-phase peptide synthesis equipment to chain them together. It’s chemistry. The barrier to entry is moderate—SPPS equipment exists, protocols are published, and compounding pharmacies invest in the capability. Quality varies because oversight varies by state.

Compounding pharmacies cannot manufacture biologics. Biologics require cell culture, fermentation, recombinant DNA technology, and manufacturing infrastructure that no compounding pharmacy possesses. If you see a compounding pharmacy claiming to make follistatin or a large protein, they are lying or they are using a compounded approximation (like cerebrolysin—a mixture derived from tissue, not pure recombinant follistatin).

FDA-approved drugs (semaglutide, tirzepatide, insulin, etc.) cannot be legally manufactured by compounding pharmacies. Compounding pharmacies can only prepare FDA-approved drugs if the drug is unavailable or if they’re creating a customized formulation (different concentration, different excipients) from an approved drug substance. They cannot synthesize semaglutide from scratch—it’s patented, and the manufacturing process is proprietary.

This is why Peptidings distinguishes between “approved” and “compounded” compounds. The category you fall into determines where you can legally source it.

↑ Back to top

Plain English FAQ

Related Guides

• The Evidence Tier System: Understanding the Research Behind Peptidings Compounds
• How to Read a Peptide Label: Purity, Concentration, and What “Pharmaceutical Grade” Actually Means
• Reconstitution Protocols: Storage, Stability, and Contamination Risk
• Growth Hormone Secretagogues: MK-677, Ipamorelin, CJC-1295, and the Quest for GH
• Semaglutide: The Modified Peptide That Changed Weight Loss
• Compounding Pharmacies vs. FDA-Approved Drugs: What You Need to Know
• Cold Chain Logistics: Why Peptides and Biologics Need Refrigeration

↑ Back to top

Summary

The distinction between small molecules, peptides, and biologics is a boundary between categories of drugs defined by size, manufacturing, and stability. These boundaries matter because they determine your route of administration (oral vs. injection), how long the compound lasts in your body, how often you need to dose, what regulatory approval looks like, and what quality standards apply.

Small molecules like MK-677 are pills—stable, orally bioavailable, and cheap to manufacture. Peptides like BPC-157 and ipamorelin are injections with short half-lives and frequent dosing requirements. Modified peptides like semaglutide blur the boundary, extending half-life to a week through engineering. Biologics like follistatin are large proteins that require recombinant manufacturing and have strict quality requirements.

Peptidings always qualifies these distinctions because they’re not just nomenclature—they’re practical information about how the compound behaves in your body. When you see “MK-677 (not a peptide)” or “semaglutide is heavily modified,” the note is telling you something important: this compound works differently from the unmodified peptides around it. That difference is worth understanding.

↑ Back to top

---